Show simple item record

dc.contributor.authorYong, K.
dc.contributor.authorWilson, W.
dc.contributor.authorCamilleri, M.
dc.contributor.authorRamasamy, K.
dc.contributor.authorStreetly, M.
dc.contributor.authorSive, J.
dc.contributor.authorBygrave, C. A.
dc.contributor.authorChapman, M.
dc.contributor.authorde Tute, R. M.
dc.contributor.authorChavda, S. J.
dc.contributor.authorPhillips, Elizabeth H
dc.contributor.authorCuadrado, M. D. M.
dc.contributor.authorPang, G.
dc.contributor.authorJenner, R.
dc.contributor.authorDadaga, T.
dc.contributor.authorKamora, S.
dc.contributor.authorCavenagh, J.
dc.contributor.authorClifton-Hadley, L.
dc.contributor.authorOwen, R. G.
dc.contributor.authorPopat, R.
dc.date.accessioned2022-10-19T13:13:22Z
dc.date.available2022-10-19T13:13:22Z
dc.date.issued2021en
dc.identifier.citationYong K, Wilson W, Camilleri M, Ramasamy K, Streetly M, Sive J, et al. Upfront Autologous Stem Cell Transplantation (ASCT) Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Consolidation in Transplant-Eligible, Newly Diagnosed (NDTE) Multiple Myeloma (MM): Results of the Cardamon Study According to Cytogenetic Risk. Blood. 2021 Nov;138. PubMed PMID: WOS:000736413903204.en
dc.identifier.doi10.1182/blood-2021-147771en
dc.identifier.urihttp://hdl.handle.net/10541/625650
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1182/blood-2021-147771en
dc.titleUpfront autologous stem cell transplantation (ASCT) Vs carfilzomib-cyclophosphamide-dexamethasone (KCD) consolidation in transplant-eligible, newly diagnosed (NDTE) multiple myeloma (MM): results of the cardamon study according to cytogenetic risken
dc.typeMeetings and Proceedingsen
dc.contributor.departmentCancer Institute, Department of Haematology, University College London, London, United Kingdomen
dc.identifier.journalBlooden
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record